Literature DB >> 263308

Growth failure with normal serum RIA-GH and low somatomedin activity: somatomedin restoration and growth acceleration after exogenous GH.

A A Kowarski, J Schneider, E Ben-Galim, V V Weldon, W H Daughaday.   

Abstract

Two three-year-old boys with dwarfism (height ages 1-4/2 and 1-11/12 years) and delayed bone ages (1-4/12 and 1-9/12 years) had normal growth hormone (GH) responses after stimulation and low levels of somatomedin. Unlike patients with Laron syndrome, the two patients generated normal levels of somatomedin after administration of exogenous hGH. Treatment with hGH (2 IU every other day) brought about a significant increase in the growth rate of both patients. The growth rate of the first patient increased from 2 cm/year before treatment to 12 cm/year on therapy. The growth rate of the second patient was 4.5 cm/year before treatment, and 8.3 cm/year while on treatment. The two cases represent a new syndrome of dwarfism which may be caused by secretion of a biologically inactive but immunoreactive GH.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 263308     DOI: 10.1210/jcem-47-2-461

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Biologically inactive growth hormone caused by an amino acid substitution.

Authors:  Y Takahashi; H Shirono; O Arisaka; K Takahashi; T Yagi; J Koga; H Kaji; Y Okimura; H Abe; T Tanaka; K Chihara
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  Molecular heterogeneity of human GH: from basic research to clinical implications.

Authors:  C L Boguszewski
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

Review 3.  Growth hormone and IGF-1.

Authors:  Roberto Salvatori
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

Review 4.  Growth hormone insensitivity: diagnostic and therapeutic approaches.

Authors:  S Kurtoğlu; N Hatipoglu
Journal:  J Endocrinol Invest       Date:  2015-06-11       Impact factor: 4.256

5.  Short stature explained by dimerization of human growth hormone induced by a p.C53S point mutation.

Authors:  Max Sander; Zida Wu; Christian J Strasburger
Journal:  J Biol Chem       Date:  2020-03-04       Impact factor: 5.157

6.  Severe short stature and endogenous growth hormone resistance in twin brothers without growth hormone gene mutations.

Authors:  Emily C Walvoord; Kyle W Sloop; Conor J Dwyer; Simon J Rhodes; Ora H Pescovitz
Journal:  Endocrine       Date:  2003-08       Impact factor: 3.633

7.  Coeliac disease in children of short stature without gastrointestinal symptoms.

Authors:  L Stenhammar; S P Fällström; G Jansson; U Jansson; T Lindberg
Journal:  Eur J Pediatr       Date:  1986-08       Impact factor: 3.183

Review 8.  Growth hormone - past, present and future.

Authors:  Michael B Ranke; Jan M Wit
Journal:  Nat Rev Endocrinol       Date:  2018-03-16       Impact factor: 43.330

9.  Radiographic abnormalities in Laron dwarfism.

Authors:  M Vasil; A Baxova; K Kozlowski
Journal:  Pediatr Radiol       Date:  1994

10.  Pseudopituitary dwarfism due to resistance to somatomedin: a new syndrome.

Authors:  J R Bierich; H Moeller; M B Ranke; R G Rosenfeld
Journal:  Eur J Pediatr       Date:  1984-08       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.